Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Withdrawn × Clonidine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Neoplasms, Second Primary 1 Neoplasms 1

Interventions

Cyclophosphamide 22 pembrolizumab 19 Cisplatin 15 Nivolumab 14 Fluorouracil 14 Capecitabine 13 Leucovorin 12 Carboplatin 12 Bevacizumab 12 Oxaliplatin 11 Radiotherapy 10 Lenalidomide 10 Dexamethasone 10 fludarabine 9 avelumab 9 Taxes 9 Rituximab 9 Gemcitabine 9 Radiosurgery 8 Azacitidine 8 venetoclax 7 fludarabine phosphate 7 Irinotecan 7 Ipilimumab 7 Docetaxel 7 ALT-803 7 Omacor 6 Melphalan 6 Interleukin-2 6 Etoposide 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00166686 2013-01-11

Clonidine for Neurocognitive Sequelae

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Phase 1/2 Withdrawn

Neoplasms, Neoplasms, Second Primary

Data powered by HemOnc (CC BY 4.0) Colophon ⚡